New data at ESMO Congress 2021 demonstrates clinical application of Predicine’s liquid biopsy solutions in breast cancer

HAYWARD, Calif.: HAYWARD, Calif., Sept. 28, 2021 /PRNewswire-PRWeb/ -- Predicine, Inc. announces results from a liquid biopsy study demonstrating the clinical application of utilizing the PredicineCAREā„¢ liquid biopsy NGS assay to detect somatic mutations and copy number variations (CNVs) in women with metastatic breast cancer at the time of diagnosis...

Click to view original post